BRAF and neoplasm: Analyses of the mutational landscape of serrated lesions have identified an activating BRAF mutation as a key alteration in the serrated neoplasia pathway, which is present in 70%–81% of SSLs [59] and results in the constitutive upregulation of the MAPK signaling cascade (Fig. 3a).